Sign Out
Patients who are hypersensitive to moxifloxacin, other excipients in the tablet, or other quinolones.
Pregnant and breastfeeding women.
Children and adolescents under the age of 18.
Patients with a history of tendon disease or disorders related to quinolone medication.
Both in preclinical and clinical studies, heart electrophysiological changes have been observed after exposure to moxifloxacin, in the form of QT prolongation. Therefore, this drug is contraindicated in patients with: Congenital or a history of QT prolongation.
Electrolyte disturbances, especially hypokalemia that cannot be corrected.
Clinically relevant bradycardia.
Clinically relevant heart failure, with reduced left ventricular ejection fraction.
History of symptomatic arrhythmias.
